Related Experiment Video
Updated: Aug 10, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
A monoclonal antibody specific for human thymidine kinase 1
Researchers developed new monoclonal antibodies (MAbs) against thymidine kinase 1 (TK1), a key tumor marker. These MAbs offer a promising, less cumbersome alternative for early cancer detection and prognosis.
Area of Science:
- Biochemistry
- Oncology
- Immunology
Background:
- Thymidine kinase 1 (TK1) is a validated prognostic and diagnostic tumor marker.
- Current radioisotope assays for TK1 are complex, limiting clinical use in cancer management.
Purpose of the Study:
- To develop novel monoclonal antibodies (MAbs) against TK1.
- To overcome limitations of existing TK1 radioisotope assays for improved cancer diagnostics.
Main Methods:
- Purified TK1 from Raji cell extract was used for MAb production.
- Antibody specificity was confirmed via Western blot, immunohistochemistry, TK1 activity inhibition assays, and ELISA.
Main Results:
- Successfully produced and validated monoclonal antibodies specific to TK1.
- Demonstrated the potential of these MAbs as diagnostic and prognostic tools.
Conclusions:
- Developed specific monoclonal antibodies (MAbs) for thymidine kinase 1 (TK1).
- These MAbs represent a potential advancement for early cancer detection, prognosis, and studying TK1's cellular functions.
More Related Videos
08:32Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors
Published on: June 7, 2018
10:44A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants
Published on: August 9, 2019
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Receptor Tyrosine Kinases
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...